Focus on Innovation

Animal Health

At Animal Health we focus our research and development activities on antiparasitics, antibiotics, medicines to treat noninfectious disorders and nonantibiotic alternatives for infectious diseases. We endeavor to improve the health and well-being of companion and farm animals through innovations that also include digital solutions. Here Animal Health also pursues the “one health” concept: we offer animal health products that reduce the risk of transmission of disease pathogens to humans, such as endoparasiticides for cats and dogs or ectoparasiticides to protect especially against fleas and ticks. Through our initiative focusing on companion vector-borne diseases (CVBD) and with the leading global scientists who participate in this initiative, we are setting trends in the establishment of scientific principles and the fight against vector-borne diseases.

Our central research activities are conducted through the Life Sciences This term describes Bayer’s activities in health care and agriculture and comprises the Bayer Group excluding its legally independent subsidiary Covestro. It refers to the businesses of the Pharmaceuticals, Consumer Health and Crop Science divisions and the Animal Health business unit. platform in conjunction with the research and development department at Pharmaceuticals and in close collaboration with Crop Science.

New products and registrations

In January 2017, the European regulatory authorities approved a new product to protect honey bees against the Varroa mite. Before the product can be marketed, this decision must be implemented in national law.


Animal Health reinforces its business by continually identifying further product development candidates through new and existing collaborations.

In May 2016, we entered into an agreement with BioNTech AG, Germany, to develop novel mRNA vaccines and therapeutics specifically for veterinary medicine applications.

Also in May 2016, we signed a global license agreement with TransferTech Sherbrooke, Quebec, Canada, to advance a novel vaccine candidate developed at Université de Sherbrooke. The new vaccine is intended to help protect dairy cattle from mastitis caused by the bacterium Staphylococcus aureus.